C5 and paroxysmal nocturnal hemoglobinuria: More recently, iptacopan, an oral complement factor B inhibitor; danicopan, an add-on therapy for C5 inhibitors; pegcetacoplan, a C3 inhibitor; and crovalimab, another C5 inhibitor, have also received US Food and Drug Administration (FDA) approval for the treatment of PNH.